Nuvectra is nothing more than a Boston Scientific knock-off. Nevro is a one trick pony that has to be recharged everyday. Medtronic can't get low back coverage to save their life. St. Jude's ridiculous study on "burst" doesn't even equate to "1" full VAS point difference from their "tonic" stim, not to mention no low back coverage. So tell me one reason why ANYONE would want to use a company other than Boston Scientific to treat a patient with low back pain or low back with a leg component... not to mention it's the only complete wireless system on the market.
How about 5? 1. Nevro is clinically proven to provide more pain relief than BSX with durability to 24 mos for patients with low back and leg pain. (That's kind of a big deal) 2. Nevro crushed BSX in a head to head study, the largest ever done in SCS history, and designed with FDA guidance. It's level 1 data. The only kind payers care about. 3. Nevro is so much better that the FDA granted superiority labeling and CMS has granted it a code capturing additional reimbursement. 4. Nevro is the only 100% parathesia free system - requires no intra-operative mapping. 5. Patients do not care about daily charging. Its easy to do, and takes 30 mins. For someone with chronic pain its a very small trade off for superior pain relief. Many patients actually prefer a daily charge to a 3hr charge once a week. So you tell me, why would ANYONE want a clinically inferior system like Boston Scientific?
I guess that all depends on what Nevro's "one trick" is. From all the data I've seen, it would be superior pain relief to paresthesia-based SCS. That's a pretty good "trick".
According to their earning call yesterday they are the NUMBER 2 and in a free fall. For a company competing in $1.5 billion dollar market to only have annualized revenue of $12MM after 1 year and with the experienced management team they have, its alarming. 2017 will be the end of them.
Nuvectra posted $12.5 million in revenue for 2016 with an estimated 40+ territories? A loss of $38.4 million for the year... Ouch.
yeah, integer's share holders are going wish they just pocketed that 75mil and cut their losses before all is said and done.
Didn't ANS grow for many years with numerous warning letters and minimal new products? If they could survive and thrive I guess anyone could and Medtronic as well
wouldn't exactly say that medtronic neuro is thriving... Nevro and Boston are eating their lunch - at least in my market.
What is the sales culture like at Nevro? It seems like morale is low despite having a pretty great product.
Because they know they are a one trick pony and the long term stats are going to be dismal. They are already the #1 x planted device and we haven't even gotten to the 2 year mark.
Is there any written data available on x-plant rates. Is the claim above verifiable? If so, very interesting for Nuvectra.
